Demand grows for early access to promising cancer drugs.
Baldwin
Joyce
J
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D016527:Drug Costs; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D000077156:Gefitinib; D006297:Health Services Accessibility / Q000592:standards*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D010344:Patient Advocacy; D011799:Quinazolines / Q000008:administration & dosage; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011799:Quinazolines; D000077156:Gefitinib